Abstract
Purpose Parkinson’s disease (PD) is a neurodegenerative disorder associated with progressive disability. While the precise aetiology is unknown, there is evidence of significant genetic and environmental influences on individual risk. The Australian Parkinson’s Genetics Study (APGS) seeks to study patient-reported data from a large cohort of individuals with PD in Australia to understand the sociodemographic, genetic, and environmental basis of PD susceptibility, symptoms and progression.
Participants In the pilot phase reported here, 1,819 participants were recruited through assisted mailouts facilitated by Services Australia (formerly known as the Australian Government Department of Human Services), based on having three or more prescriptions for anti-PD medications in their Pharmaceutical Benefits Scheme (PBS) records. The average age at the time of the questionnaire was 64 ± 6 years. We collected patient-reported PD information and socio-demographic variables via an online (93% of the cohort) or paper-based (7%) questionnaire. 1,532 participants (84.2%) had a current PD diagnosis and consented to provide a DNA sample via a saliva sampling kit sent by traditional post. Of these, 1435 (94%) returned the saliva samples for genotyping.
Findings to date 65% of participants were male, and 92% identified as being of European descent. A previous traumatic brain injury was reported by 16% of participants and was associated with a younger age of symptom onset. At the time of the questionnaire, constipation (36% of participants), depression (34%), anxiety (17%), melanoma (16%) and diabetes (10%) were the most commonly reported comorbid conditions.
Future plans We are actively seeking funding to expand the project’s scope and reach, including recruiting unaffected controls, and a follow-up questionnaire focused on non-motor symptoms and cognitive function assessment. Future work will explore the role of genetic and environmental factors in the aetiology of PD susceptibility, onset, symptoms and progression, including as part of international PD research consortia.
Strengths and limitations of this study
We showed that recruiting Australian participants for PD research through the PBS database is feasible and a highly efficient method and enables us to reach people all over Australia who have been prescribed medications used to treat Parkinson’s symptoms.
The Australian Parkinson’s Genetics Study (APGS) is the most extensive nation-wide genetic study of Parkinson’s disease (PD) in Australia (n = 1,532 in its pilot phase). It will serve as a platform for advancing PD research in the country.
As part of this pilot, we collected patient-reported outcomes and variables relevant to disease onset, diagnosis, symptoms, medical comorbidities and family history. Information on environmental exposures, lifestyle factors, ethnicity and socio-demographic variables were also included.
A general limitation is that traditional motor-related PD symptoms can most reliably be assessed during a clinical visit. Also, patient-reported data may be subject to a degree of attribution or recall bias for items concerning the age of symptom onset or the environmental and occupational exposures.
Competing Interest Statement
CRS has collaborated with Pfizer, Opko, Proteome Sciences, Genzyme Inc; has consulted for Genzyme; has served as Advisor to the Michael J. Fox Foundation, NIH, Department of Defense; is on the Scientific Advisory Board of the American Parkinson Disease Association; has received funding from the NIH, the U.S. Department of Defense, the Harvard NeuroDiscovery Center, the Michael J. Fox Foundation, and American Parkinson Disease Association. XD has received funding from the NIH, the Michael J. Fox Foundation, and American Parkinson Disease Association.
Funding Statement
The APGS mailout was primarily funded by National Health and Medical Research Council (NHMRC) and the Australian Research Council (ARC) through an NHMRC-ARC Dementia Research Development Fellowship award to MER (GNT1102821). AIC and LMGM are supported by UQ Research Training Scholarships from The University of Queensland (UQ). JG thanks the NHMRC (1127440) and Mater Foundation for support. SEM is supported by an NHMRC Investigator grant (APP1172917).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been approved by the Human Research Ethics Committee of the QIMR Berghofer Medical Research Institute.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
: Data is available upon reasonable request for research purposes, in anonymised form, to preserve participants' identity. Inquiries from potential scientific collaborators can be directed to the corresponding author (Miguel.Renteria@qimrberghofer.edu.au).
